Search results for "aav"
Article
Successful Development of Scalable AAV Processes: Part 2 of 2
Watch the Q&A interview >>
In the second of a two-part series, Anki Magnusson, Staff Research Engineer, Protein and Viral Production, and Åsa Hagner-McWhirter, PhD, Senior Scientist, Bio…
Article
Top Challenges to Overcome When Developing AAV Processes: Part 1 of 2
Watch the Q&A interview >>
In the first of a two-part series, Anki Magnusson, Staff Research Engineer, Protein and Viral Production, and Åsa Hagner-McWhirter, PhD, Senior Scientist…
Article
How to Optimize and Scale Up AAV Production
In this article from a roundtable discussion, four experts from academia and industry met to discuss challenges in refining and scaling up AAV production pipelines to meet the increasing demand for …
Article
Future-proof your AAV process with a complete producer cell line – just induce and grow
To deliver on the promise of AAV-based gene therapy for prevalent diseases, we need similar technology. The challenge is that multiple genetic elements – rep, helper, capsid, and gene of interest – mu…
Article
Gene Therapies Push Viral Vector Production
By Feliza Mirasol
Several virus types have been studied for use as viral vectors in gene therapy, including adenovirus, lentivirus, retrovirus, and adeno-associated virus (AAV). Of these, AA…
Article
A Look at the Affinity Chromatography Landscape
The greatest demand is for lentiviral and adeno-associated viral (AAV) vectors, with sourcing of lentiviral vectors becoming a bottleneck for gene and cell therapy manufacturing.
Traditionally,…
Article
A Closer Look at Affinity Ligands
A key step in the production of gene therapy products is the use of high-quality viral vectors with [AAV] vector and lentiviral vector (LV) being the most popular platforms. Robust manufacture of high…
Article
Single-Use Technologies Prove Effective for Viral Vector Process Development
Notably for the manufacture of vectors based on adeno-associated virus (AAV), one of the most common vector types for gene therapy delivery and viral-vector vaccines, recent data have shown that stain…
Article
Scaling Up Novel Therapies
Great improvements have been seen so far in delivering adeno-associated virus (AAV) vectors. These results demonstrate the inextricable link between clinical work and process development, said Kathy H…
Article
Report from the 6th International HTPD Conference
Beyond mAbs: AAV and mRNA process development were discussed at HTPD 2023
Since the clinical pipeline is becoming more and more diversified, novel types of biomolecules have also become more in…